OBD has completed a validation trial of its EpiSwitchTM melanoma test, stratifying melanoma patients from non-melanoma skin cancer patients – Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC) and other skin lesions. Whole venous blood samples of 116 melanoma and 170 non-melanoma skin cancer patients were analysed in the study. The multivariate molecular biomarker test included 15 epigenetic biomarkers and shows high accuracy, sensitivity and PPV.